MedTrace Logo

GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy

NCT01147029 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-05-01

No results posted yet for this study

Summary

RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not responded to therapy.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

angiogenesis inhibitor GSAO

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Sponsors & Collaborators

Principal Investigators

  • Gordon Jayson, MD · The Christie NHS Foundation Trust

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147029 on ClinicalTrials.gov